Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 596.91% and ...
forcing the company to invest heavily to increase production. Eli Lilly has invested more than $20 billion to buy, build and ...
Eli Lilly has again upped the ante in scaling up its manufacturing footprint, this time revealing an investment totaling $1.8 billion to expand production capacity at two plants in Ireland. | Eli ...
Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...
As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up to release their own treatments, aiming to challenge the two industry ...
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...
Bristol Myers Squibb, AstraZeneca, Eli Lilly and other drug companies have invested some $10 billion on promising cancer ...
Nearly $1 billion will go toward expanding a facility that last year began making medicines for the company's new diabetes and obesity treatments.
Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...
The first notable agency action in 2024 is the FTC’s Second Request in Novo Holding’s proposed $16.5 billion acquisition of Catalent, a life sciences contract manufacturer. 1 The agency’s interest in ...
It’s here, roughly 10 minutes from town, that US pharmaceutical giant Eli Lilly & Co. is making its latest push to slake the unprecedented demand for its blockbuster drugs, Mounjaro and Zepbound. The ...
Demand for Eli Lilly's Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily to increase production.